← Back to Search

Radiation Therapy

Pre-Surgery Radiation for Early-Stage Breast Cancer

N/A
Waitlist Available
Led By Sasha Beyer, MD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4-6 weeks post-apbi
Awards & highlights
No Placebo-Only Group

Summary

This trial studies radiation therapy given before surgery to reduce tumor size and minimize tissue removal in older patients with early breast cancer.

Who is the study for?
This trial is for women over 50 with stage I breast cancer that's hormone responsive and hasn't spread. They must be able to have an MRI, lie prone during treatment, and agree to surgery after radiation. Excluded are those with large tumors (>3cm), prior breast treatments, or certain other cancers within the last 5 years.
What is being tested?
The study tests if giving a high-dose radiation therapy called intensity-modulated accelerated partial breast irradiation (APBI) before surgery can shrink tumors more effectively while sparing healthy tissue in older patients with early-stage hormone-positive breast cancer.
What are the potential side effects?
Potential side effects of APBI may include skin irritation, fatigue, pain or discomfort at the treatment site, changes in breast size or shape, and rare risks associated with anesthesia during subsequent surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4-6 weeks post-apbi
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4-6 weeks post-apbi for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The primary endpoint will be the reproducibility of the MRI directed preoperative APBI treatment method
Secondary study objectives
Exploratory evaluation of patient breast cancer tissue and serum for CSCs, biomarkers and miRNAs

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (image-guided intensity-modulated APBI)Experimental Treatment4 Interventions
Patients undergo image-guided intensity-modulated APBI twice daily (BID) in the prone position over a period of 5-10 days for a total of 10 treatment. Within 4-6 weeks post-APBI, patients undergo lumpectomy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
therapeutic conventional surgery
2003
Completed Phase 3
~12900
accelerated partial breast irradiation
2009
N/A
~190
image-guided radiation therapy
2008
Completed Phase 2
~180
intensity-modulated radiation therapy
2008
Completed Phase 3
~1490

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
340 Previous Clinical Trials
293,288 Total Patients Enrolled
23 Trials studying Breast Cancer
2,902 Patients Enrolled for Breast Cancer
Sasha Beyer, MDPrincipal InvestigatorOhio State University Comprehensive Cancer Center
1 Previous Clinical Trials
4 Total Patients Enrolled
Julia White, MDPrincipal InvestigatorOhio State University Comprehensive Cancer Center
1 Previous Clinical Trials
4 Total Patients Enrolled

Media Library

Accelerated Partial Breast Irradiation (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02186470 — N/A
Breast Cancer Research Study Groups: Treatment (image-guided intensity-modulated APBI)
Breast Cancer Clinical Trial 2023: Accelerated Partial Breast Irradiation Highlights & Side Effects. Trial Name: NCT02186470 — N/A
Accelerated Partial Breast Irradiation (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02186470 — N/A
~2 spots leftby Dec 2025